

Contents

Preface — V

List of contributing authors — XV

Wolfram Klapper

- 1 Classification of lymphomas – past, present and future — 1**
 - 1.1 Classification – what is it good for? — 1
 - 1.2 The history of lymphoma classification — 2
 - 1.2.1 19th century: Tumors of lymphoid cells and their relation to leukemia — 2
 - 1.2.2 20th century: Description of individual diseases and historical lymphoma classifications — 3
 - 1.2.3 The second half of the 20th century: Modern lymphoma classifications, controversy and consensus — 4
 - 1.3 The principles of the current WHO classification — 6
 - 1.4 Future lymphoma classification – towards new hierarchical classification principles? — 8

Ulf Klein and Nilushi S. De Silva

- 2 Mature B-cell development and the germinal center reaction — 13**
 - 2.1 Introduction — 13
 - 2.2 The peripheral B-cell repertoire — 15
 - 2.3 The germinal center reaction — 16
 - 2.3.1 Initiation of the GC reaction — 16
 - 2.3.2 GC formation and establishment of the mature GC — 18
 - 2.3.3 Somatic hypermutation — 19
 - 2.3.4 B cell movements within the zonal structure of the GC — 21
 - 2.3.5 Selection of high-affinity GC B cells — 22
 - 2.3.6 Class switch recombination — 24
 - 2.3.7 GC maintenance — 24
 - 2.3.8 Termination of the GC reaction and post-GC B-cell differentiation — 28
 - 2.4 Concluding remarks — 29

Shan Zha and Jennifer L. Crowe

- 3 T-cell development — 37**
 - 3.1 Introduction — 37
 - 3.2 Overview — 37
 - 3.3 $\alpha\beta$ T-cell repertoire — 38
 - 3.3.1 Antigen presentation and MHC molecules — 38
 - 3.3.2 Peripheral $\alpha\beta$ TCR repertoires — 39

3.4	The T-cell receptor —	41
3.4.1	The variable chains of the T-cell receptor —	41
3.4.2	The order and regulation of V(D)J recombination —	41
3.4.3	Molecular mechanism of V(D)J recombination —	43
3.4.4	Tumorigenic potential of TCR recombination —	44
3.5	Thymus and early T-cell development —	44
3.5.1	The thymus —	44
3.5.2	Early T-cell development in the thymus —	45
3.5.3	Positive selection —	47
3.5.4	CD4 vs CD8 lineage commitment —	48
3.5.5	Negative selection and exit from the thymus —	49
3.6	TCR signaling – T-cell activation —	49
3.6.1	TCR signaling complex —	49
3.6.2	Activation and survival of naive T cells —	50
3.6.3	Activated T-cell differentiation —	51
3.6.4	Shutting down activated T cells —	52
3.7	Concluding remarks —	53

Beiyang Dai, Andre Weilemann, and Georg Lenz

4	Mantle cell lymphoma —	61
4.1	Introduction —	61
4.2	Molecular pathogenesis of MCL —	62
4.2.1	Overexpression of cyclin D1 and cell cycle dysregulation —	62
4.2.2	Additional genetic aberrations and deregulated signaling pathways —	63
4.3	Clinical implications —	68
4.4	BCR signaling inhibitors —	68
4.5	PI3K/mTOR inhibitors —	69
4.6	BCL2 inhibitors —	69
4.7	Proteasome inhibitors —	69
4.8	Concluding remarks —	70

Jessica Okosun and Jude Fitzgibbon

5	Follicular lymphoma —	75
5.1	Introduction —	75
5.2	Histology and grading —	75
5.3	Transformed follicular lymphoma —	76
5.4	Early steps of FL development: Initial genetic hit t(14;18) —	76
5.5	Cell of origin —	77
5.6	t(14;18) insufficient for lymphoma development —	78
5.7	Intermediate steps in FL development —	78
5.8	Existence of a progenitor clone —	80

5.9	Molecular genetics of FL — 81
5.9.1	Copy number alterations and copy neutral loss of heterozygosity — 81
5.9.2	Genetic aberrations affecting key biological and signaling pathways — 81
5.9.3	Alterations in epigenetic regulators — 82
5.9.4	Alterations in immune modulators — 84
5.9.5	Alterations affecting NF-κB signaling — 85
5.9.6	Alterations affecting JAK-STAT signaling — 85
5.9.7	Alterations affecting genes involved in cell proliferation and cell cycle regulation — 86
5.9.8	Alterations in miscellaneous genes — 87
5.10	Disease progression, transformation and clonal evolution — 87
5.11	Other FL variants: Pediatric and t(14;18)-negative follicular lymphoma — 89
5.12	Impact of the tumor microenvironment — 90
5.13	Susceptibility loci for FL — 91
5.14	Concluding remarks — 91

Ming-Qing Du

6	Genetics and molecular pathogenesis of marginal zone lymphoma — 101
6.1	Introduction — 101
6.2	Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue — 101
6.2.1	Etiology of MALT lymphoma — 101
6.2.2	Role of immunological stimulation in the pathogenesis of MALT lymphoma — 102
6.2.3	Genetic abnormalities in MALT lymphoma — 104
6.2.4	Oncogenic cooperation between genetic abnormalities and antigenic stimulation — 110
6.3	Splenic marginal zone lymphoma — 111
6.3.1	Etiology of SMZL — 111
6.3.2	Role of antigenic drive in pathogenesis of SMZL — 112
6.3.3	Genetic abnormalities in SMZL — 112
6.3.4	Oncogenic cooperation between genetic changes and antigenic stimulation — 116
6.4	Concluding remarks — 117

David Dominguez-Sola and Riccardo Dalla-Favera

7	Burkitt lymphoma — 127
7.1	Introduction — 127
7.2	Cellular origin of Burkitt lymphoma — 127
7.3	Genetic lesions involved in BL pathogenesis — 128

- 7.3.1 Chromosomal translocations involving the c-MYC proto-oncogene — **128**
- 7.3.2 Mutations in TCF3 and ID3, and activation of PI3K signaling — **132**
- 7.3.3 Additional recurrent genetic lesions — **132**
- 7.4 Mouse models of Burkitt lymphoma — **134**
- 7.5 Conclusions and perspectives — **134**

Laura Pasqualucci

- 8 Diffuse large B-cell lymphoma — 139**
- 8.1 Introduction — **139**
- 8.2 Cell of origin and classification — **139**
- 8.2.1 The “cell-of-origin” (COO) classification — **141**
- 8.2.2 The “comprehensive-consensus-cluster” (CCC) classification — **143**
- 8.3 Mechanisms of genetic lesion in DLBCL — **143**
- 8.3.1 Chromosomal translocations — **144**
- 8.3.2 Aberrant somatic hypermutation — **144**
- 8.4 The genetic landscape of DLBCL — **145**
- 8.5 Dysregulated pathways in DLBCL — **146**
- 8.5.1 Programs dysregulated in both GCB-DLBCL and ABC-DLBCL — **146**
- 8.5.2 Genetic lesions associated with GCB-DLBCL — **152**
- 8.5.3 Genetic lesions associated with ABC-DLBCL — **155**
- 8.5.4 Genetic lesions associated with histologic transformation of FL and CLL — **158**
- 8.6 Double-hit DLBCL — **159**
- 8.7 Concluding remarks — **160**

Christian Steidl and Randy D. Gascoyne

- 9 The biology of primary mediastinal large B-cell lymphoma — 171**
- 9.1 Introduction — **171**
- 9.2 Cell of origin and gene expression profiling — **172**
- 9.3 Molecular hallmarks of PMBCL — **174**
- 9.3.1 The mutational landscape of primary mediastinal large B-cell lymphoma — **175**
- 9.3.2 JAK-STAT pathway signaling — **175**
- 9.3.3 NF- κ B signaling — **179**
- 9.3.4 Acquired immune privilege — **180**
- 9.3.5 Epigenetic changes — **182**
- 9.3.6 Biomarkers and therapeutic considerations — **183**
- 9.4 Concluding remarks — **186**

James L. Rubenstein

- 10 Molecular pathogenesis of primary central nervous system lymphoma — 193**
 - 10.1 Introduction — 193
 - 10.2 Etiology — 193
 - 10.3 Clinical features and pathogenesis — 194
 - 10.4 Molecular pathogenesis of PCNSL — 195
 - 10.5 Role of the tumor microenvironment in PCNSL — 199
 - 10.6 Concluding remarks — 200

Davide Rossi and Gianluca Gaidano

- 11 Chronic lymphocytic leukemia — 205**
 - 11.1 Introduction — 205
 - 11.2 Clinical background — 205
 - 11.3 B-cell receptor signaling pathway — 207
 - 11.4 Notch signaling pathway — 209
 - 11.5 Other signaling pathways — 212
 - 11.6 Splicing — 213
 - 11.7 Apoptotic and cell cycle checkpoints — 216
 - 11.8 MYC network — 220
 - 11.9 Telomere function — 221
 - 11.10 Clonal architecture and evolution of CLL — 221
 - 11.11 Inherited susceptibility of CLL — 222
 - 11.12 Concluding remarks — 223

Zachary R. Hunter, Jorge J. Castillo, and Steven P. Treon

- 12 Waldenström's macroglobulinemia — 229**
 - 12.1 Introduction — 229
 - 12.2 Epidemiology and patient characteristics — 229
 - 12.3 Nature of the WM clone — 230
 - 12.4 Chromosomal abnormalities in WM — 231
 - 12.5 MYD88 somatic mutations — 232
 - 12.6 CXCR4 somatic mutations — 234
 - 12.7 Other recurrent mutations — 237
 - 12.8 Microenvironmental interactions in WM — 238
 - 12.9 Concluding remarks — 238

Marta Chesi and P. Leif Bergsagel

- 13 Molecular pathogenesis of multiple myeloma — 245**
 - 13.1 Introduction — 245
 - 13.2 Clinical stages of plasma cell neoplasms: a new definition of multiple myeloma — 245

- 13.3 Chromosome translocations of the immunoglobulin genes are present in half of patients with MGUS and MM — **246**
- 13.4 Three groups of primary IgH translocations in ~ 40 % of MM — **247**
- 13.5 Hyperdiploidy with multiple trisomies is another primary genetic event — **249**
- 13.6 Universal dysregulation of a cyclin D/RB axis in MM — **249**
- 13.7 Secondary genetic events associated with progression of MGUS to MM — **249**
 - 13.7.1 MYC — **249**
 - 13.7.2 Deletion 13 — **251**
 - 13.7.3 RAS pathway — **251**
- 13.8 High-risk MM is associated with subclonal tumor heterogeneity — **252**
- 13.9 Concluding remarks and future directions — **253**

Ralf Küppers

- 14 Biology of Hodgkin's lymphoma — 257**
 - 14.1 Introduction — **257**
 - 14.2 The cellular origin of the tumor cells in HL — **258**
 - 14.3 Relationship of Hodgkin cells to Reed–Sternberg cells — **260**
 - 14.4 The lost B-cell identity of HRS cells — **261**
 - 14.5 Genetic lesions — **263**
 - 14.6 Role of EBV in HL pathogenesis — **266**
 - 14.7 Deregulated signaling pathways and transcription factors — **267**
 - 14.8 Microenvironmental interactions — **269**
 - 14.9 Lessons learnt from composite lymphomas — **271**
 - 14.10 HL cell lines — **272**

Brunangelo Falini and Stefano Pileri

- 15 Anaplastic large cell lymphoma — 285**
 - 15.1 Introduction — **285**
 - 15.2 Anaplastic large cell lymphoma, ALK-positive (ALK⁺ ALCL) — **285**
 - 15.2.1 Clinical features — **286**
 - 15.2.2 Morphology — **286**
 - 15.2.3 Immunohistochemical markers — **288**
 - 15.2.4 Patterns of ALK protein expression in ALK⁺ ALCL — **289**
 - 15.2.5 Differential diagnosis — **292**
 - 15.2.6 Genetic abnormalities and molecular pathogenesis of ALK⁺ ALCL — **294**
 - 15.2.7 Prognostic factors and therapy — **296**
 - 15.3 Anaplastic large cell lymphoma, ALK-negative (ALK⁻ ALCL) — **297**
 - 15.3.1 Epidemiology — **297**
 - 15.3.2 Clinical features — **297**

- 15.3.3 Morphology and phenotype — 297
- 15.3.4 Molecular studies — 300
- 15.3.5 Prognosis — 301
- 15.4 Primary cutaneous ALCL — 301
- 15.5 Breast-implant ALCL — 302

José Rodríguez Cortés, Adolfo Ferrando, and Teresa Palomero

16 Molecular pathogenesis of malignant lymphomas: PTCL, NOS and AITL — 311

- 16.1 Introduction — 311
- 16.2 Follicular helper T cells in the pathogenesis of AITL — 312
- 16.3 Gene expression profiling insights in the classification and biology of PTCL, NOS and AITL — 314
- 16.4 The genetic landscape of AITL and PTCL, NOS — 315
- 16.5 Lessons from animal models — 319
- 16.6 Concluding remarks — 322

Wing C. Chan

17 Extranodal NK/T-cell lymphoma — 329

- 17.1 Introduction — 329
- 17.2 General clinicopathologic features — 329
- 17.3 Receptor expression — 330
- 17.4 The role of EBV in pathogenesis — 332
- 17.5 Genetic and epigenetic alterations — 334
- 17.6 $\gamma\delta$ T-cell lymphoma — 338
 - 17.6.1 Cell of origin — 338
 - 17.6.2 Subtypes of lymphomas derived from $\gamma\delta$ T cells — 338
 - 17.6.3 Hepatosplenic $\gamma\delta$ T-cell lymphoma — 339
 - 17.6.4 Primary cutaneous $\gamma\delta$ T-cell lymphoma — 340
 - 17.6.5 Mucosal $\gamma\delta$ T-cell lymphoma — 340
 - 17.6.6 $\gamma\delta$ T-cell lymphoma in the intestine — 341
- 17.7 Gene expression profiling analysis — 342
- 17.8 JAK/STAT pathway activation — 344
- 17.9 Concluding remarks — 345

Ethel Cesarman

18 Lymphomas associated with viral infection — 351

- 18.1 Introduction — 351
- 18.2 Epstein–Barr virus (EBV) — 352
 - 18.2.1 Patterns of EBV latency — 352
 - 18.2.2 EBV mediated lymphomagenesis — 354
 - 18.2.3 Lymphomas associated with EBV infection — 356

18.3	Kaposi's sarcoma-associated herpesvirus (KSHV) —	359
18.4	KSHV-mediated lymphomagenesis —	359
18.4.1	Lymphomas associated with KSHV infection —	360
18.5	Human T-cell leukemia virus-1 (HTLV-1) —	364
18.5.1	HTLV-1 mediated oncogenesis —	364
18.5.2	Adult T-cell leukemia-lymphoma (ATL) —	364
18.6	Hepatitis C virus —	366
18.7	HIV and lymphomagenesis —	366
18.8	Concluding remarks —	367

Loïc Ysebaert, Roch Houot, and Franck Morschhauser

19	Translating science into therapy of lymphoma —	379
19.1	Introduction —	379
19.2	Inhibition of the B-cell receptor signaling pathway —	381
19.2.1	Historical overview of BTK/PI3K inhibitors —	381
19.2.2	Tumor hyperlymphocytosis —	382
19.2.3	Diffuse large B-cell lymphoma —	382
19.2.4	Follicular lymphoma —	383
19.2.5	Waldenström's macroglobulinemia (WM) —	384
19.2.6	Marginal zone lymphomas —	384
19.2.7	Chronic lymphocytic leukemia —	385
19.2.8	Mantle Cell Lymphoma —	386
19.3	Inducing the mitochondrial apoptosis pathway in lymphoma —	387
19.4	Targeting ALK in lymphoma —	388
19.5	Targeting immune cells in lymphoma —	389
19.5.1	Lenalidomide —	389
19.5.2	Immune checkpoints inhibitors —	389
19.6	Targeting epigenetic deregulation —	391
19.6.1	EZH2 inhibitors —	391
19.6.2	IDH2 —	391
19.7	Concluding remarks —	392

Index — 403